Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Bradykinin peptide icon, one bubble per amino acidBradykinin9 residuesRPPGFSPFREach bubble = one amino acid. Size = residue mass. Color = chemical class.

Bradykinin

ImmuneResearch
~15-30 seconds half-life·Injection·2w on / 4w off

Also known as: BK, Kallidin I, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg

Fifteen seconds of plasma survival. That's the operating window for one of the most potent vasodilators the human body produces. Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) crashes blood pressure, opens vascular gates for immune cells, and fires pain signals almost before ACE can chew it apart. Rocha e Silva first isolated this 9-amino-acid peptide in 1949. Billions of ACE inhibitor prescriptions later, cardiovascular researchers still circle back to bradykinin for answers about endothelial function and angioedema. Intra-arterial infusion at 10 to 100 nmol/min remains the gold-standard test. Nobody self-administers this peptide, and the pharmacology explains why.

What Is Bradykinin?

Fewer than 30 seconds of plasma survival, yet decades of cardiovascular research built on top of it. Bradykinin (CAS 58-82-2, sequence Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is a 9-amino-acid vasoactive peptide generated when kallikrein cleaves high-molecular-weight kininogen.

The signaling runs through two receptors. B2 sits on vascular endothelium constitutively. When bradykinin binds, eNOS fires and prostacyclin production kicks in. Blood pressure drops. Vascular permeability increases. Pain receptors activate. Then ACE (kininase II) cleaves the Pro7-Phe8 bond and the whole signal disappears.

That ACE connection is where bradykinin matters most in clinical medicine. Every ACE inhibitor prescription works partly by preventing bradykinin breakdown. The dry cough affecting a significant fraction of users? Bradykinin accumulation in pulmonary tissue. The angioedema risk? Same pathway. Chowienczyk and colleagues established the canonical human forearm protocol: intra-arterial brachial infusion at 10 to 100 nmol/min, measuring blood flow by venous occlusion plethysmography [1].

Bradykinin also sits at the center of hereditary angioedema. C1-inhibitor deficiency causes uncontrolled bradykinin production and severe episodic swelling. Icatibant, an FDA-approved B2 receptor antagonist, treats HAE attacks by blocking bradykinin directly (reviewed in the FAST-3 trial)[2]. Community self-administration does not exist; subcutaneous bioavailability lands below 5%.

How Bradykinin Works

Two receptors run the bradykinin program. B2 sits on vascular endothelial cells at baseline. B1 stays mostly silent until tissue injury or cytokines (IL-1-beta, TNF-alpha) flip the switch.

When bradykinin docks with B2, Gaq signaling triggers phospholipase C. PLC generates IP3 and DAG from membrane phospholipids. IP3 pulls calcium from intracellular stores. That calcium spike activates eNOS; nitric oxide floods into the surrounding smooth muscle. Guanylyl cyclase converts GTP to cGMP. The muscle relaxes. The vessel dilates.

A parallel arm fires simultaneously. Phospholipase A2 frees arachidonic acid. Cyclooxygenase converts it to prostacyclin (PGI2). Two vasodilatory cascades hitting at once explains why bradykinin is so potent.

Bradykinin also triggers tPA release from endothelial cells. Fibrinolysis runs alongside vasodilation. On sensory neurons, B2 activation sensitizes TRPV1 channels and boosts sodium channel conductivity. Pain thresholds drop sharply.

The B1 receptor tells a separate story. Des-Arg9-bradykinin, a metabolite, activates it. NF-kB signaling sustains chronic inflammation. B1 only matters during tissue injury, but once upregulated, it shifts the response from acute vasodilation toward persistent inflammatory signaling. ACE destroys bradykinin in 15 to 30 seconds (Murphey et al., J Pharmacol Exp Ther, 2000). Carboxypeptidase N strips the C-terminal arginine, producing the B1-active metabolite.

Bradykinin Benefits

  • Bradykinin benefits center on vascular function and immune response in the context of endogenous physiology, not exogenous therapy.
  • Vasodilation through dual pathways (nitric oxide and prostacyclin) produces rapid blood pressure reduction. Chowienczyk et al. measured 2 to 4x increases in forearm blood flow at 100 nmol/min intra-arterial infusion [1].
  • Tissue plasminogen activator release from endothelial cells promotes fibrinolysis. This direct link between the kinin system and clot breakdown partly explains the cardiovascular protection seen with ACE inhibitors.
  • Vascular permeability regulation enables immune cell trafficking to injury sites during the acute inflammatory response.
  • Renal sodium excretion modulation contributes to long-term blood pressure homeostasis. Marceau and Regoli mapped these downstream effects across multiple tissue types [3].
  • Endothelial cell survival signaling through B2 receptor pathways supports angiogenesis and vascular repair over time.
  • Prostaglandin E2 synthesis feeds into inflammatory resolution. The system starts the fire and helps put it out.

Bradykinin: Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 3 key studies·Research only

Bradykinin is one of the most extensively studied endogenous vasoactive peptides in cardiovascular and inflammatory research.

Dosing studied: 10–100 nmol/min intra-arterial infusion (research endothelial function testing); 100 nmol intradermal (pain/vascular permeability research). No validated subcutaneous dosing protocol exists.
Read the evidence (key study, limitations)

Intra-arterial infusion is the established research method for assessing endothelial vasodilatory function in humans. No validated therapeutic protocol exists for exogenous administration: indirect pharmacological strategies (ACE inhibitors, kallikrein inhibitors, B2 antagonists) are the established clinical approach to the kinin system.

Key Study

Chowienczyk PJ et al. "Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization." Hypertension. 2000. PMID: 10856283.: Canonical human forearm intra-arterial bradykinin infusion methodology.

Limitations

All human data involves intra-arterial or intravenous infusion under controlled conditions with continuous hemodynamic monitoring. No oral, subcutaneous, or intranasal bioavailability data exists for therapeutic use. Half-life of ~15-30 seconds makes sustained systemic exposure from any peripheral route essentially impossible without continuous infusion.

Community Experience
Weak
2.0/5
Based on effectively zero: no documented community self-administration reports found

No meaningful community self-administration exists.

Community dosing: N/A: no community dosing protocol documented
Read the reports (common issues 4)

Bradykinin does not appear in peptide community forums (Reddit r/Peptides, r/PEDs, etc.) as a self-administered compound. The ultra-short half-life, requirement for IV/IA delivery, and potent vasoactive risk profile make it impractical and dangerous outside a clinical research environment.

What users report (0)
    Common issues (4)
    • Extreme hypotension risk without monitoring equipment
    • Ultra-short half-life renders SC injection pharmacologically pointless
    • Angioedema risk including airway compromise
    • No community experience base to draw protocols from
    Science-Only Evidence

    Community has not adopted bradykinin as a self-administered peptide. All use is confined to controlled research settings. The science is well-established for research applications; the community segment does not apply.

    Bradykinin Dosage Guide

    SpeculativeVery limited human dosing data: extrapolated from pharmacology research
    LevelDose / InjectionFrequency
    Beginner25 mcg
    DailyTrack
    Moderate50 mcg
    DailyTrack
    Aggressive100 mcg
    DailyTrack
    Note:

    Bradykinin isn't something you reconstitute at home with an insulin syringe. This peptide belongs in a monitored research facility with continuous blood pressure tracking and emergency airway equipment on standby.

    Reconstitution math for reference: a 1 mg vial with 2 mL bacteriostatic water gives 500 mcg/mL. On a 100-unit insulin syringe, each unit equals 5 mcg. A 25 mcg dose would be 5 units; 100 mcg would be 20 units. Those numbers are mostly academic, though. Research protocols use calibrated infusion pumps delivering 10 to 100 nmol/min intra-arterially, not bolus injections.

    The half-life situation makes bradykinin unique among peptides. At 15 to 30 seconds, you can't maintain plasma levels with intermittent dosing. Continuous infusion is the only route to sustained pharmacological effect. Subcutaneous bioavailability sits below 5% because tissue kininases destroy the peptide before it reaches systemic circulation.

    Bradykinin is sold only as a lab reagent for research. Grey-market research peptides don't meet the analytical standards needed for a compound going into arteries. Verify endotoxin content below 1 EU/mg before any in vivo work.

    Cycling Protocol

    On Period
    2 weeks
    Off Period
    4 weeks

    Due to extreme vasoactive potency and risk of B1 receptor upregulation with repeated exposure, only very short research cycles are appropriate. Extended use is not recommended. Continuous hemodynamic monitoring required during administration.

    Calculate your Bradykinin dose
    Free dosage calculator with syringe visualization

    Or use the universal Peptide Calculator for any peptide.

    Bradykinin Protocols by Goal

    advancedClinical TrialSingle research session (~2–3 hours total including prep and recovery)
    Baseline hemodynamic stabilization
    Wk 0 (pre-infusion)
    N/A · N/A · intra-arterial (brachial artery)
    Dose-escalation infusion
    Wk 0 (single session)
    10 → 25 → 50 → 100 nmol/min · Each dose level infused for 6 minutes; 4 escalation steps · intra-arterial (brachial artery)
    Recovery monitoring
    Wk 0 (post-infusion)
    N/A · N/A · N/A

    Expected: Dose-dependent increase in forearm blood flow demonstrating endothelium-dependent vasodilation. Used as a surrogate measure of endothelial NO and prostacyclin production capacity.

    Monitor: Continuous intra-arterial blood pressure, heart rate, oxygen saturation. Vasopressor (phenylephrine) and icatibant (B2 antagonist) immediately available as rescue. Angioedema assessment at each step.

    How to Inject Bradykinin

    1. 1
      Step 1

      Reconstitute lyophilized bradykinin acetate with bacteriostatic water. For a 1 mg vial, adding 2 mL gives 500 mcg/mL. Add water slowly along the vial wall and swirl gently.

    2. 2
      Step 2

      Transfer reconstituted solution to a calibrated syringe pump. Standard intra-arterial methodology uses dose escalation: 10 nmol/min, then 25, then 50, then 100 nmol/min. Each step runs for 6 minutes with a 10-minute washout between levels.

    3. 3
      Step 3

      Establish continuous intra-arterial blood pressure monitoring before starting any infusion. IV access for fluid bolus and vasopressor support must be in place first.

    4. 4
      Step 4

      Have icatibant (30 mg prefilled syringe for subcutaneous injection) and epinephrine (0.3 mg IM auto-injector) at the bedside. Standard antihistamines will not treat bradykinin-mediated angioedema.

    5. 5
      Step 5

      Monitor for systolic BP drop exceeding 30 mmHg from baseline, heart rate above 120 bpm, facial or tongue swelling, or wheezing. Any trigger means immediate infusion stoppage.

    6. 6
      Step 6

      After the final infusion step, monitor for at least 30 minutes. Direct peptide effects resolve within 1 to 2 minutes given the 15-second half-life, but localized edema can persist for 30 to 60 minutes.

    7. 7
      Step 7

      Store reconstituted bradykinin at 2 to 8 degrees Celsius and use within 5 days. Aliquot immediately to avoid freeze-thaw degradation.

    Needle gauge: not applicable for standard IA infusion protocols (delivered via catheter). For subcutaneous pain research models, 27-30 gauge insulin syringes are typical.

    Syringe unit reference (1 mg / 2 mL reconstitution): 5 units = 25 mcg, 10 units = 50 mcg, 20 units = 100 mcg on a standard 100-unit insulin syringe.

    Mixing your own vial? Use the Bradykinin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Bradykinin Stacking Protocols

    Works With

    L-NMMA (research co-infusion)

    Mechanistic research only: L-NG-monomethyl arginine co-infusion blocks eNOS to isolate the NO-independent component of bradykinin vasodilation. Not a therapeutic stack.

    Avoid

    ACE inhibitors (lisinopril, enalapril, ramipril, etc.)

    ACE is the primary enzyme degrading bradykinin (kininase II). ACE inhibitors block this degradation, dramatically prolonging and potentiating all bradykinin effects: vasodilation, angioedema risk, pain sensitization. Co-administration is dangerous and unpredictable.

    Do not combine
    Neprilysin inhibitors (sacubitril/valsartan: Entresto)

    Neprilysin is a secondary bradykinin-degrading enzyme. Neprilysin inhibition further elevates bradykinin levels. Combined with exogenous bradykinin, risk of severe hypotension and angioedema markedly increased.

    Do not combine
    ARBs (losartan, valsartan, irbesartan)

    ARBs partially potentiate bradykinin via AT2 receptor crosstalk and may reduce bradykinin clearance. Lower severity than ACE inhibitors but still warrants caution.

    VIP (Vasoactive Intestinal Peptide)

    Both bradykinin and VIP are potent vasodilators acting through complementary pathways (bradykinin via NO/PGI2; VIP via cAMP/adenylyl cyclase). Additive hypotensive effect with no safety data for combined use.

    Do not combine

    Estimated Cost

    Bradykinin Side Effects

    Severe hypotension tops the risk profile. Bradykinin causes rapid, dose-dependent vasodilation that can crash systolic blood pressure by more than 30 mmHg within seconds of intra-arterial delivery. That speed leaves almost no time for compensatory baroreflexes. Research protocols using the Chowienczyk methodology [1] stop infusion immediately at that threshold.

    Angioedema is the second most dangerous concern. Bradykinin directly increases vascular permeability independent of histamine. Swelling of the face, tongue, lips, or airway can develop during or shortly after administration. The distinction matters: bradykinin-mediated angioedema does not respond to antihistamines or corticosteroids. Icatibant (30 mg subcutaneous) is the specific B2 receptor antagonist rescue agent. Epinephrine 0.3 mg intramuscular is indicated if airway compromise develops.

    Published research consistently reports pain and burning at the infusion site. This is direct nociceptor activation through B2 receptor sensitization of TRPV1 channels. Dose-dependent, transient, resolves within minutes of stopping the infusion. Researchers consider it confirmatory of bioactivity.

    Bronchoconstriction can develop, particularly in people with asthma or reactive airway disease. Bradykinin sensitizes bronchial nociceptors and triggers parasympathetic reflexes. Spirometry screening before any research exposure is standard practice.

    Reflexive tachycardia follows the blood pressure drop. Heart rate exceeding 120 bpm triggers protocol stoppage in most research designs. Flushing, nausea, and headache are frequent at higher infusion rates.

    Repeated exposure introduces a longer-term concern. B1 receptors, normally near-silent, get upregulated by inflammatory cytokines and repeated bradykinin stimulation. This shifts the pharmacological profile from acute vasodilation toward chronic NF-kB-mediated inflammatory signaling. Research protocols space sessions at least one week apart to allow B1 normalization.

    Mast cell activation with histamine release can layer additional allergic-type responses on top. Pregnancy is a strict contraindication; vasoactive effects may compromise placental perfusion. Concurrent ACE inhibitor use dramatically potentiates all effects by blocking bradykinin degradation.

    Stop administration and seek emergency care for facial swelling, tongue thickening, difficulty breathing, or sustained systolic below 80 mmHg.

    Common Issues & Solutions

    Hypotension during infusion: Stop infusion immediately: effects resolve within 1–2 minutes given ultra-short half-life. Supine positioning and IV fluid bolus typically sufficient. Vasopressor only if systolic remains <80 mmHg after 2 min.

    Angioedema onset: Administer icatibant (30 mg SC) as B2 receptor antagonist rescue. Epinephrine 0.3 mg IM if airway compromise. Do NOT use antihistamines alone: bradykinin-mediated angioedema is histamine-independent.

    Prolonged vasodilation (>5 min after infusion stop): Suspect concurrent ACE inhibitor exposure. Review medication history. Consider icatibant as rescue.

    Bronchoconstriction: Bradykinin directly sensitizes airway nociceptors. Administer short-acting bronchodilator (salbutamol). Screen for asthma before any research exposure.

    Pain/burning at infusion site: Expected pharmacological effect from direct B2 receptor nociceptor sensitization. Dose-dependent and transient. Reduce infusion rate; do not attempt to mask with analgesics that may confound study endpoints.

    Ask AI about this page

    Ask AI for a second opinion on Bradykinin dosing and side effects

    Contraindications

    • Hypotension or hemodynamic instability: bradykinin causes profound vasodilation
    • History of angioedema (hereditary or ACE inhibitor-induced)
    • Concurrent ACE inhibitor therapy: dramatically potentiates bradykinin effects
    • Asthma or reactive airway disease: risk of bronchoconstriction
    • Pregnancy: vasoactive effects may compromise placental perfusion
    • Severe cardiovascular disease or recent myocardial infarction

    Drug Interactions

    • ACE inhibitors (enalapril, lisinopril, ramipril): prevent bradykinin degradation, markedly potentiating effects and risk of angioedema
    • ARBs (losartan, valsartan): may modestly potentiate bradykinin via AT2 receptor crosstalk
    • NSAIDs (ibuprofen, aspirin): block prostacyclin synthesis, partially attenuating bradykinin-mediated vasodilation
    • Icatibant (B2 receptor antagonist): directly blocks bradykinin effects, used as rescue in research protocols
    • Neprilysin inhibitors (sacubitril): reduce bradykinin degradation, increasing accumulation
    • Vasopressors (norepinephrine, phenylephrine): may be required to counteract severe hypotension
    • ARBs partially potentiate bradykinin via AT2 receptor crosstalk and may reduce bradykinin clearance. Lower severity than ACE inhibitors but still warrants caution.

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Continuous intra-arterial blood pressureThroughout every infusion sessionSystolic >90 mmHg; stop infusion if SBP drops >30 mmHg from baseline
    Heart rate / ECGThroughout infusion sessionHR <120 bpm; stop infusion and assess if persistent tachycardia
    Airway and angioedema assessmentBefore, during, and 30 min after infusionNo visible facial, lip, tongue, or laryngeal edema
    Forearm blood flow (venous occlusion plethysmography)During each dose step in endothelial function research2–4x increase from baseline expected at 100 nmol/min IA
    Spirometry / peak flow (if asthma history)Before infusion session; immediately if any wheeze detectedNot listed
    Continuous intra-arterial blood pressure

    Bradykinin causes rapid, profound vasodilation: BP drop is the primary safety concern during IA/IV administration

    Heart rate / ECG

    Reflexive tachycardia expected; arrhythmia possible with severe hypotension

    Airway and angioedema assessment

    Bradykinin is the primary mediator of hereditary angioedema; any facial/tongue swelling requires immediate icatibant administration

    Forearm blood flow (venous occlusion plethysmography)

    Primary efficacy endpoint for vasodilatory capacity measurement

    Spirometry / peak flow (if asthma history)

    Bradykinin directly sensitizes bronchial nociceptors and can cause bronchoconstriction, particularly in atopic individuals

    Bradykinin Before and After

    Seconds
    0-30s

    Immediate B2 receptor activation upon administration. Rapid onset of vasodilation, nitric oxide release, and drop in local or systemic blood pressure. Peak plasma levels achieved almost instantaneously with IV/IA delivery. Degradation by ACE begins immediately.

    Minutes
    1-5 min

    Maximal vasodilatory response observed. Increased vascular permeability and plasma extravasation at target tissue. Nociceptor sensitization and pain signaling detectable. Most of the administered peptide has been degraded by this point.

    Minutes
    5-30 min

    Hemodynamic parameters begin returning to baseline following cessation of infusion. Residual inflammatory signaling may persist via prostaglandin and NO pathways. Localized edema may take longer to resolve.

    Hours
    1-6 hr

    Direct peptide effects have fully dissipated. Secondary inflammatory mediators (prostaglandins, cytokines) may sustain mild local inflammation. B1 receptor upregulation begins if tissue injury or cytokine exposure is ongoing.

    Days
    1-3 days

    With repeated daily dosing in research protocols, measurable upregulation of B1 receptors at target tissue. Shift from acute B2-mediated to chronic B1-mediated signaling may alter inflammatory profile. Full vascular recovery expected within 24 hours of last dose.

    What to Expect

    0 to 30 seconds, Peak pharmacological activity: B2 receptors fire the instant bradykinin reaches the endothelium. eNOS generates nitric oxide. Vasodilation peaks within 15 to 30 seconds of intra-arterial delivery. ACE is already shredding the peptide. Flushing, burning at the infusion site, and a sharp drop in local vascular resistance happen almost simultaneously.

    1 to 5 minutes, Maximal vasodilatory window: Forearm blood flow hits peak levels on plethysmography. Vascular permeability spikes at the infusion site. PGI2 and prostaglandin E2 synthesis ramp up in parallel. Over 90% of the administered peptide has been degraded by kininases. Reflexive tachycardia, headache, and possible systemic blood pressure drop if IV delivery was used.

    5 to 15 minutes after infusion stops, Rapid resolution: Blood pressure and heart rate return to baseline. NO and prostacyclin production cease. Some prostaglandin signaling persists briefly. No drug accumulation between dose steps if the 10-minute washout period was honored. Residual flushing fades; localized edema may take 30 to 60 minutes to fully clear.

    Hours with repeated sessions, B1 receptor upregulation: B1 receptors, normally barely expressed, increase with repeated tissue exposure or inflammatory stimulation. Subsequent bradykinin exposures produce stronger inflammatory signaling through NF-kB activation. Research protocols space sessions at least a week apart to let B1 levels normalize. Amplified pain responses and shifted inflammatory profiles become the concern with repeat exposure.

    Detailed Timeline: Science vs Community

    0–30 seconds
    Science

    Maximal B2 receptor activation. Rapid eNOS stimulation and NO release. Vasodilation peaks within 15–30 seconds of intra-arterial delivery. Simultaneous kininase II degradation begins immediately.

    Community

    No community data: research setting only.

    1–5 minutes
    Science

    Peak forearm blood flow increase measurable by plethysmography. Vascular permeability increase at infusion site. Prostaglandin E2 and PGI2 synthesis underway. >90% of administered peptide degraded by kininases.

    Community

    No community data.

    5–15 minutes after infusion stops
    Science

    Hemodynamic parameters return to baseline. NO and PGI2 production ceases. Residual prostaglandin signaling may persist briefly. No accumulation between dose steps if washout period honored.

    Community

    N/A

    Hours (with repeated research sessions)
    Science

    With repeated tissue exposure or inflammatory stimulation, B1 receptor expression increases (normally near-zero at baseline). Subsequent bradykinin challenges may produce stronger inflammatory signaling via B1-mediated NF-κB activation. Relevant to multi-session research designs.

    Community

    N/A

    Pharmacokinetics

    Half-Life
    0min
    Bioavailability
    <5% subcutaneous (near-complete first-pass degradation by tissue and plasma kininases)
    Tmax
    <15 seconds IV; ~1-2 minutes subcutaneous
    Data Confidence
    high

    Source: Murphey et al., J Pharmacol Exp Ther, 2000: measured plasma bradykinin half-life ~15-27 seconds in humans

    Molecular Profile

    Amino Acids
    9
    Sequence
    RPPGFSPFR
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

    Who Should Consider Bradykinin

    • Cardiovascular researchers studying endothelial function and vasodilation
    • Scientists investigating the kallikrein-kinin system and ACE inhibitor mechanisms
    • Clinicians researching hereditary angioedema pathophysiology
    • Pain researchers studying nociceptor sensitization and inflammatory hyperalgesia
    • Pharmacologists developing kinin receptor modulators
    • Researchers exploring vascular permeability and inflammatory edema

    Related Peptides

    What Changed for Bradykinin

    No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

    Peptide Schedule Research TeamReviewed Apr 8, 20263 Citations

    References

    1. [1]Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization (Honing et al., Hypertension 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Icatibant for the treatment of hereditary angioedema (opens in a new tab)PubMed (opens in a new tab)Review
    3. [3]The kallikrein-kinin system: current and future pharmacological targets (opens in a new tab)PubMed (opens in a new tab)Review

    Related Tools

    Storage & Stability

    Before Reconstitution
    Store at -20°C for long-term stability, up to 2 years. Protect from light and moisture.
    After Reconstitution
    Refrigerate at 2-8°C, use within 5 days. Aliquot immediately to avoid freeze-thaw degradation.
    Temperature
    -20°C (long-term) or 2-8°C (short-term)

    Frequently Asked Questions

    Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, CAS 58-82-2) is a 9-amino-acid peptide that acts through B2 receptors (constitutive) and B1 receptors (induced by inflammation). It is an endogenous vasodilator and pain mediator with a plasma half-life of roughly 15-30 seconds due to rapid degradation by kininases. Research use focuses on vascular biology and inflammation models.

    Bradykinin is primarily used as a research tool for studying vascular permeability, inflammatory pain pathways, and the kallikrein-kinin system. ACE inhibitor cough (the classic side effect) occurs because ACE normally degrades bradykinin; blocking ACE raises bradykinin levels in lung tissue. This pharmacological relationship drives a significant portion of cardiovascular research interest.

    Exogenous bradykinin causes rapid vasodilation, hypotension, pain at the infusion site, and potential bronchoconstriction. The 15-30 second half-life limits systemic duration but means effects are intense and immediate. Angioedema (severe swelling) is the most serious risk, particularly in patients with hereditary angioedema or those taking ACE inhibitors. This is a research tool, not a therapeutic peptide.

    Yes. Bradykinin is sold only as a lab reagent for research, in research-grade lyophilized form. It is not compounded by pharmacies and has no therapeutic indication. Typical research quantities are 1-5 mg vials used for in vitro and animal model experiments.

    Bradykinin dosing varies by experience level. Beginners typically start at 25 mcg daily, moderate users at 50 mcg daily, and aggressive protocols use 100 mcg daily.